Navigation Links
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Date:4/30/2009

after the call.

To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The teleconference replay will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 95970767. The webcast will remain available on the company's website until the next earnings call.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfenidone analog named ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) expected to enter Phase 2b in the summer of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without lim
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 30
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. InterMune to Present at Canaccord Adams Hepatitis C Conference
4. InterMune to Present at Citis 4th Annual Biotech Day
5. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
6. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
7. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
8. InterMune Announces Issuance of U.S. Patent for ITMN-191
9. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
10. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
11. InterMune to Present at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 Whitehouse Laboratories has formally ... Stability Testing and Package Test Capacity. Responding to growing ... a dramatic increase in environmental chamber storage space that ... and aging samples to be securely held on site ... capital expenditure has already taken place with the recent ...
(Date:10/30/2014)... , Oct. 30, 2014 Isis Pharmaceuticals, Inc. ... today announced that management will present a company overview at ... 8:30 a.m. ET in Boston, MA. ... available on the "Investors & Media" section of the Company,s ... the Isis website within 48 hours and will be archived ...
(Date:10/30/2014)... of the key challenges in the development of quantum ... , In a paper published today (28 October) in ... show how to make a new type of flexibly ... such as high-precision sensors and specialised superfast computers, often ... the methods for trapping these tiny particles are hugely ...
(Date:10/27/2014)... The new research report, “Gas ... Medium), Sub-type (Primary & Secondary), and End-User (Transmission ... & Power Generation) - Trends and Forecasts to ... analysis and forecasting of the market size. , ... 52 Figures spread through 146 Pages and in-depth ...
Breaking Biology Technology:Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4
... AMSTERDAM, October 13 Amsterdam Molecular,Therapeutics ... gene therapy,announced today that the European Medicines Agency has ... for the treatment of,Duchenne muscular dystrophy. , ... (DMD) entitles,AMT to ten year market exclusivity in Europe ...
... HAIKOU CITY, China, Oct. 12 ... CPHI ), which develops,manufactures, and markets specialty pharmaceutical ... the Roth China Conference, to be held,October 12-14, 2009, ... participate in one-on-one meetings with conference attendees throughout,the three-day ...
... 12 Dr. Michael Merzenich , PhD ... brain plasticity expert and tech entrepreneur - was ... Washington, D.C. Also a member of the National Academy of ... scientists and doctors in the U.S. who have been selected ...
Cached Biology Technology:AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy 2AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy 3Dr. Michael Merzenich Joins Venerable Short List Honored for Cutting-Edge Neuroscientific Research 2Dr. Michael Merzenich Joins Venerable Short List Honored for Cutting-Edge Neuroscientific Research 3
(Date:10/30/2014)... UT Arlington bioengineering professor has received a $1.04 ... to regenerate cartilage tissue and reduce osteoarthritis using ... injection of microscaffolding made of biodegradable polymers., Liping ... the bioengineering department, said the research is primarily ... on the battlefield., "We,ve found that if we ...
(Date:10/30/2014)... Philadelphia, PA, October 30, 2014 – Bacteria in ... are critical for digestion. Yet, these same bacteria ... system if they penetrate the gut and enter ... natural response to protect the body, chronic or ... diseases. Prior research has established the involvement of ...
(Date:10/29/2014)... by unconventional oil and gas production are well over ... the open access journal Environmental Health . High ... The study is the first to be based on ... and could be used to supplement official air-quality monitoring ... that do not readily flow to the surface. This ...
Breaking Biology News(10 mins):UTA researcher uses microscaffolding injections to mend cartilage, prevent osteoarthritis 2Breakdown in gut barriers to bacteria may promote inflammation and craving in alcoholics 2Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3
... Chicago, IllinoisJune 22, 2010"Seasick: Ocean Change and the ... in the US by the University of Chicago Press, ... in Environmental Reporting. Awarded by the Metcalf Institute for ... of the environment and recognizes reporting that has the ...
... puzzled over why a baby,s brain is particularly flexible ... have to learn a lot? A group of researchers ... Institute for Dynamics and Self-Organization in Gttingen, the Schiller ... put forward a new explanation: Maybe it is because ...
... (June 20, 2010) By emulating nature,s design principles, ... Engineering, Harvard Medical School and Dana-Farber Cancer Institute has ... be programmed to move and change shape on demand. ... highly suitable for medical applications because DNA is both ...
Cached Biology News:Growing brain is particularly flexible 2Researchers create self-assembling nanodevices that move and change shape on demand 2
... Cell Lines ,High Quality, Functionally-Validated, Ion Channel ... known for having a critical role in ... a key function in pain, CNS and ... have been investigated in therapeutic areas, such ...
Mouse polyclonal antibody raised against a partial recombinant CD320. NCBI Entrez Gene ID = 51293...
Mouse monoclonal antibody raised against a partial recombinant CHD8. NCBI Entrez Gene ID = CHD8...
Mouse monoclonal antibody raised against a partial recombinant DENR. NCBI Entrez Gene ID = DENR...
Biology Products: